Advertisement
News
Advertisement

Breakthrough in the Fight Against Drug-resistant Superbugs

Tue, 08/19/2014 - 11:51am
E. coli, one of the bacteria killed by the new antibacterial gel.Scientists at Queen’s University Belfast have made a breakthrough in the fight against the most resistant hospital superbugs.
 
The team from the School of Pharmacy at Queen’s have developed the first innovative antibacterial gel that acts to kill Pseudomonas aeruginosa, staphylococci and E. coli using natural proteins.
 
The gels have the ability to break down the thick jelly-like coating, known as biofilms, which cover bacteria making them highly resistant to current therapies, while leaving healthy cells unaffected.
 
“When bacteria attach to surfaces, including medical implants such as hip replacements and catheters, they produce a jelly-like substance called the biofilm. This protective layer is almost impossible for current antibiotics to penetrate through," said Dr. Garry Laverty, lead researcher from the School of Pharmacy at Queen’s University. "Therefore bacteria deep within this protective layer are resistant as they remain unexposed to the therapy. They grow and thrive on surfaces to cause infections that are very difficult to treat. The only option is often to remove the medical implant leading to further pain and discomfort for the patient. Our gels would prevent this."
 
Laverty added: “Our gels are unique as they target and kill the most resistant forms of hospital superbugs. It involves the use of gels composed of the building blocks of natural proteins, called peptides. The same ingredients that form human tissue. These molecules are modified slightly in the laboratory to allow them to form gels that will rapidly kill bacteria. This is further evidence of Queen’s research advancing knowledge and changing lives.”
 
The new approach, which was developed as part of an international collaboration between the School of Pharmacy at Queen’s and the School of Chemistry at Brandeis University, Waltham, Massachusetts, will be published in the journal Biomacromolecules.
 
The results will form part of a presentation delivered by Laverty at the Academy of Pharmaceutical Sciences, UK PharmSci: The Science of Medicines conference at the University of Hertfordshire on the Sept. 8.
 
Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading